A cohort study of the risk factors and the target AUC to avoid vancomycin-associated acute kidney injury in pediatric patients

Naoko Kanazawa, Akari Shigemi, Nao Amadatsu, Kotaro Arimura, Shohei Shimono, Kazutaka Oda, Victor Tuan Giam Chuang, Kazuaki Matsumoto, Hideki Kawamura, Hideyuki Terazono

Research output: Contribution to journalArticlepeer-review

1 Citation (Scopus)


Objectives: In recent years, Vancomycin (VCM) dosing design using area under the concentration-time curve (AUC) has been recommended as a measure of efficacy and safety, but there are fewer reports on pediatric patients than on adults. In this study, we evaluated the threshold of AUC for AKI occurrence in pediatric patients and investigated the factors that contribute to the occurrence of AKI. Methods: Pediatric patients aged 1–15 years on VCM treatment who underwent TDM at Kagoshima University Hospital from April 2016 to March 2022 were included in the computation of AUC using pediatric population pharmacokinetic parameters. Results: The ROC curve showed that the AUC threshold for the risk of developing AKI was 583.0 μg・h/mL, and the AUC-ROC curve was 0.873 (sensitivity 0.930, specificity 0.750). Univariate analysis showed that factors associated with AKI incidence were the duration of VCM administration, ICU admission, and AUCSS. Concomitant medications identified as risk factors for AKI incidence were tazobactam/piperacillin, liposomal amphotericin B, calcineurin inhibitors, contrast agents, and H2-receptor blockers. The multivariate analysis showed that AUC ≧ 583.0 μg・h/mL (odds ratio 20.14, 95% CI 3.52–115.22, p < 0.001) and H2-receptor blockers (odds ratio 8.70, 95% confidence interval = 1.38–54.87, p = 0.02) were independent factors for AKI incidence. Conclusions: We showed that in pediatric patients receiving VCM, the risk of AKI increases as AUC increases. The findings imply that concurrent use of VCM and H2-receptor blockers may increase the risk of AKI.

Original languageEnglish
Pages (from-to)323-328
Number of pages6
JournalJournal of Infection and Chemotherapy
Issue number4
Publication statusPublished - 2024 Apr

ASJC Scopus subject areas

  • Microbiology (medical)
  • Infectious Diseases
  • Pharmacology (medical)


Dive into the research topics of 'A cohort study of the risk factors and the target AUC to avoid vancomycin-associated acute kidney injury in pediatric patients'. Together they form a unique fingerprint.

Cite this